

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/077929 A1

(51) International Patent Classification⁷: **A61K 31/675**,
47/14, 9/20, A61P 9/12

(21) International Application Number: **PCT/IS03/00013**

(22) International Filing Date: 19 March 2003 (19.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
6315 19 March 2002 (19.03.2002) IS

(71) Applicant (for all designated States except US): **DELTA HF** [IS/IS]; Reykjavikurvegi 78, IS-220 Hafnarfjörður (IS).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **EYJÓLFSSON, Reynir** [IS/IS]; Eyrahlóti 6, IS-220 Hafnarfjörður (IS).

(74) Agent: **A & P ARNASON**; Efstaleiti 5, IS-103 Reykjavík (IS).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **FOSINOPRIL FORMULATION**

(57) Abstract: A pharmaceutical formulation is provided comprising fosinopril which is the prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. The formulation is characterized by comprising in the range of about 0.25 to about 5% glyceryl dibehenate which has been found to be a highly useful lubricant in the manufacture of tablets according to the present invention, enhancing the stability of fosinopril as compared to prior art formulations.



WO 03/077929 A1

Fosinopril formulation**FIELD OF INVENTION**


- 5 The present invention is within the field of pharmaceuticals, particularly relating to improved formulations of the ACE inhibitor prodrug fosinopril.

TECHNICAL BACKGROUND AND PRIOR ART

10

Fosinopril is the ester prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. The compound can be used as an antihypertensive agent. Its ability to inhibit ACE and thus lower blood pressure is disclosed in US Patent no. 4,337,201. The compound (the sodium salt, which is the commonly used drug form) is designated chemically as L-proline 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy) propoxy] (4-phenylbutyl)phosphinyl] acetyl] sodium, *trans*-, see Formula (I).

15



- 20 The prodrug is converted *in vivo* into the active component by hydrolysis of the diester sidechain. Fosinopril sodium has a relatively low bulk density, exhibits poor flow characteristics, and adheres to metal surfaces during tableting. Fosinopril has been tableted by a wet granulation process using magnesium stearate as a lubricant material. Tablets produced from such blend have low stability, are moisture sensitive and require the use of a
- 25 protective package for a useful shelf life.

- US Patent no. 5,006,344 suggests the use of sodium stearyl fumarate or hydrogenated vegetable oil instead of magnesium stearate, to increase the stability of fosinopril tablets. The reference however, does not discuss why the two preferred lubricants are found to be better
- 30 than magnesium stearate, or suggest other possible lubricants. It has been suggested that the degradation of fosinopril in Mg stearate compositions is due to the effect of the Mg metal ion (Thakur, A.B. et al. *Pharm. Res.* 10 (6) 800-809 (1993)).

It has now been found that fosinopril sodium tablets comprising glyceryl dibehenate as lubricant have excellent stability. Glyceryl dibehenate has several advantages when used in fosinopril compositions as compared to other lubricants used in prior art compositions. In contrast to salts of fatty acids and fatty acid derivatives including magnesium stearate or sodium stearyl fumarate, glyceryl dibehenate is a neutral and non-metal containing compound.

In contrast to hydrogenated vegetable oil, glyceryl dibehenate is chemically a clearly defined substance and can be obtained with a well defined particle size.

SUMMARY OF INVENTION

The present invention provides a pharmaceutical formulation comprising in the range of about 1% to 25% fosinopril or a salt thereof, the formulation being characterized by comprising in the range of about 0.25 to about 5% glyceryl dibehenate.

DETAILED DESCRIPTION

The present formulation is particularly useful in tablet formulations, however, it is as well contemplated that the formulations according to the invention can be formulated for capsules, sachets, caplets or other solid dosage forms. As mentioned the formulation comprises in the range of about 1% to 25% fosinopril or a related salt thereof, preferably the sodium salt, such as about 1-10%, including about 1-5%. The formulation is characterized by comprising in the range of about 0.25 to about 5% glyceryl dibehenate, such as in the range of about 0.5-5%, or about 1-5%, e.g. in the range of about 1-2.5%, including about 1%, and about 2%, or about 2.5% of glyceryl dibehenate. All percentages used herein refer to weight percentages if not otherwise noted.

Glyceryl dibehenate may be obtained by esterification of glycerol with behenic acid (C 22:0 fatty acid). The product is provided commercially by Gattefossé s.a. under the tradename Compritol 888 ATO. Compritol has a fatty acid composition with over 83% behenic acid, 40-60% of the fatty acids are in diester form (diglycerides), and 21-35% are in triester form (triglycerides). Accordingly, useful embodiments of the invention comprise a lubricant formulation in the above amount comprising in the range of about 50-100 wt% of glyceryl di- and tribehenate, such as in the range of about 55-95 wt%, including the range of about 70-80 wt%. Such lubricant formulations would generally contain glyceryl dibehenate and glyceryl tribehenate in a ratio ranging from about 1:1 to about 3:1.

The formulation of the present invention typically further comprises conventional excipients such as a filler, a disintegrant, and a binder. In one embodiment the formulation comprises in the range of 30 to 85% of a filler substance, which may be one of numerous substances generally known in the art, such as e.g. a saccharide (e.g. lactose or mannitol) or

5 microcrystalline cellulose or a mixture thereof, and may further comprise in the range of 0.5 to 5 wt% of a disintegrant such as crosslinked sodium carboxymethylcellulose (NaCMC), crosslinked polyvinylpyrrolidone or mixtures thereof. Suitable binders include povidone (2-pyrrolidinone), hydroxypropyl cellulose, pregelatinized starch, gelatin and mixtures thereof. The formulations may additionally comprise other commonly used excipients that are

10 compatible with the active ingredient such as pigments, colorants, sweeteners, taste-masking agents and the like.

For production of tablets a direct compression or wet granulation process may be used, where the latter is presently preferred.

15 In certain embodiments the formulation of the invention further comprises in the range of about 0.5 – 50 wt% of a pharmaceutically active compound selected from the group containing diuretics including hydrochlorothiazide; antitussives including dextromethorphan, dextromethorphan hydrobromide, noscapine, carbetapentane citrate, and chlophedianol

20 hydrochloride; antihistamines including chlorpheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants including phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine; and alkaloids such as codeine phosphate, codeine sulfate, and morphine.

25 The following non-limiting examples illustrate in more detail a preferred embodiment of the invention and its advantages.

EXAMPLES

30 Example 1

The following materials were combined by wet granulation to produce 5 mg, 10 mg, and 20 mg fosinopril sodium tablets (tablet weight 100 mg, 200 mg, 200 mg respectively):

35	Fosinopril sodium	5.0 mg	10.0 mg	20.0 mg
	Lactose monohydrate	59 mg	118 mg	108 mg
	Starch, pregelatinized (starch 1500)	12 mg	24 mg	24 mg
	Crosslinked NaCMC (croscarmellose sodium)	2 mg	4 mg	4 mg
	Water, purified	q.s.	q.s.	q.s.
40	Microcrystalline cellulose	20 mg	40 mg	40 mg
	Glyceryl dibehenate*	2 mg	4 mg	4 mg

Compritol™ 888 ATO, Gattefossé s.a., France

Example 2

Stability of tablets prepared in Example 1 and of marketed preparation were tested at 40°C for one month. Hydrolysis of fosinopril into fosinoprilat was assayed and measured as relative amount of initial amount of fosinopril.

	Assay	Fosinoprilat
10 Tablets from Ex. 1	4.9 mg	1.7%
Marketed prepn**.	4.9 mg	2.6%

**Dynacil™ fosinopril sodium 5 mg tablets, containing sodium stearyl fumarate as lubricant

15

The example demonstrates a surprisingly good stability of fosinopril sodium tablets according to the present invention.

20 Example 3

The following materials are combined by wet granulation to produce tablets with 10 mg fosinopril sodium and 12.5 mg hydrochlorothiazide (tablet weight 200 mg):

25	Fosinopril sodium	10.0 mg
	Hydrochlorothiazide	12.5 mg
	Lactose monohydrate	105.5 mg
	Starch pregelatinized	24 mg
	Crosslinked NaCMC	4 mg
30	Water purified	q.s.
	Microcrystalline cellulose	40 mg
	Glyceryl dibehenate	4 mg

CLAIMS

1. A pharmaceutical formulation comprising in the range of about 1% to 25% fosinopril or a salt thereof, the formulation characterized by comprising glyceryl dibehenate as a lubricant agent.
2. The formulation of claim 1 comprising the sodium salt of fosinopril.
3. The formulation of claim 1 comprising in the range of about 0.25 to about 5% glyceryl dibehenate.
4. The formulation of claim 1 formulated in tablet dosage form.
5. The tablet formulation of claim 4 produced by wet granulation
6. The formulation of claim 1 further comprising in the range of 30 to 85 wt% of a filler substance, and in the range of 0.5 to 5 wt% of a disintegrant such as crosslinked sodium carboxymethylcellulose.
7. The formulation of claim 1 comprising about 5 wt% fosinopril sodium, about 2 wt% of a lubricant formulation comprising in the range of about 50-100 wt% glyceryl di- and tribehenate, in the range of about 50-70 wt% lactose monohydrate, about 20 wt% microcrystalline cellulose, and about 2 wt% crosslinked sodium carboxymethylcellulose.
8. The formulation of claim 1 further comprising 0.5 – 50 wt% of a pharmaceutically active compound selected from the group containing diuretics including hydrochlorothiazide; antitussives including dextromethorphan, dextromethorphan hydrobromide, noscapine, carbetapentane citrate, and chlorpheniramine hydrochloride; antihistamines including chlorpheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants including phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine; and alkaloids such as codeine phosphate, codeine sulfate, and morphine.
9. The formulation of claim 8 comprising 0.5 – 50 wt% of hydrochlorothiazide.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IS 03/00013

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/675 A61K47/14 A61K9/20 A61P9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, WPI Data, CHEM ABS Data, EMBASE, BIOSIS, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 006 344 A (JERZEWSKI ROBERT L ET AL) 9 April 1991 (1991-04-09) the whole document	1-9
P, A	US 2002/131999 A1 (SHERMAN BERNARD CHARLES) 19 September 2002 (2002-09-19) the whole document --- -/--	1-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 May 2003

Date of mailing of the international search report

- 5. 06. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

INGRID EKLUND /EÖ

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IS 03/00013

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GU L ET AL: "Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation." PHARMACEUTICAL RESEARCH. UNITED STATES APR 1990, vol. 7, no. 4, April 1990 (1990-04), pages 379-383, XP002241567 ISSN: 0724-8741 the whole document	1-9
A	AL-OMARI M M ET AL: "Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations." JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. ENGLAND JUL 2001, vol. 25, no. 5-6, July 2001 (2001-07), pages 893-902, XP002241568 ISSN: 0731-7085 the whole document	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/IS 03/00013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5006344	A	09-04-1991	AT 100321 T 15-02-1994
			CA 2019324 A1 10-01-1991
			DD 299154 A5 02-04-1992
			DE 69006125 D1 03-03-1994
			DE 69006125 T2 19-05-1994
			DK 408273 T3 28-02-1994
			EP 0408273 A1 16-01-1991
			ES 2062376 T3 16-12-1994
			JP 2965633 B2 18-10-1999
			JP 3048623 A 01-03-1991

US 2002131999	A1	19-09-2002	CA 2330904 A1 11-07-2002
			AU 1004402 A 18-07-2002
			DE 10164343 A1 29-08-2002
			GB 2372702 A 04-09-2002

THIS PAGE BLANK (USPTO)